Patients' characteristics at transplantation
| Baseline parameters . | All patients . |
|---|---|
| All patients | 71 (100) |
| Sex | |
| Male | 41 (57.8) |
| Female | 30 (43.2) |
| Median age of recipient, y (range) | 40.1 (20-64) |
| Median age of donor, y (range) | 39.8 (18.2-61.3) |
| Hematologic disease | |
| AML/ALL/MDS/MPD/AA | 25/11/9/3/1 |
| Lymphoma/myeloma | 10/12 |
| Disease status at transplantation | |
| CR | 34 (48) |
| PR or SD | 32 (45) |
| PD | 5 (7) |
| Conditioning regimen | |
| MAC | 25 (35) |
| RIC | 46 (65) |
| Donor | |
| Sibling | 43 (60) |
| Unrelated 10/10 | 21 (30) |
| Unrelated 9/10 | 7 (10) |
| Donor/recipient sex matching | |
| Female to male | 15 (21) |
| Other | 56 (79) |
| In vivo T depletion | |
| No | 39 (55) |
| Yes | 32 (45) |
| Risk of CMV | |
| Low | 20 (28.2) |
| Intermediate | 31 (43.6) |
| High | 20 (28.2) |
| HSC source | |
| BM | 21 (29.6) |
| PBSC | 50 (70.4) |
| Baseline parameters . | All patients . |
|---|---|
| All patients | 71 (100) |
| Sex | |
| Male | 41 (57.8) |
| Female | 30 (43.2) |
| Median age of recipient, y (range) | 40.1 (20-64) |
| Median age of donor, y (range) | 39.8 (18.2-61.3) |
| Hematologic disease | |
| AML/ALL/MDS/MPD/AA | 25/11/9/3/1 |
| Lymphoma/myeloma | 10/12 |
| Disease status at transplantation | |
| CR | 34 (48) |
| PR or SD | 32 (45) |
| PD | 5 (7) |
| Conditioning regimen | |
| MAC | 25 (35) |
| RIC | 46 (65) |
| Donor | |
| Sibling | 43 (60) |
| Unrelated 10/10 | 21 (30) |
| Unrelated 9/10 | 7 (10) |
| Donor/recipient sex matching | |
| Female to male | 15 (21) |
| Other | 56 (79) |
| In vivo T depletion | |
| No | 39 (55) |
| Yes | 32 (45) |
| Risk of CMV | |
| Low | 20 (28.2) |
| Intermediate | 31 (43.6) |
| High | 20 (28.2) |
| HSC source | |
| BM | 21 (29.6) |
| PBSC | 50 (70.4) |
Values are n (%) unless otherwise indicated. CMV reactivation risks were determined according to the donor (D) and recipient (R) serologies as follows: D−/R−, low risk; D+/R+ or D+/R−, intermediate risk; D−/R+, high risk.
AA indicates aplastic anemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia, CR, complete remission; HSC, hematopoietic stem cell, MAC, myeloablative conditioning; MDS, myelodysplasic syndrome; MPD, myeloproliferative disease; PD, progressive disease; PR, partial remission; PBSC, peripheral blood stem cells; and RIC, reduced-intensity conditioning.